Changing the dynamic of manufacturing and development for gene therapies
The foundation of our business is “The Hearth”, a 200,000+ ft2 custom-designed, cGMP facility, dedicated to AAV viral vector manufacturing. We offer end-to-end manufacturing and development services to accelerate gene therapy programs from preclinical, through clinical, and commercial manufacturing.Request Information
*5,000L bioreactors available in the second half of 2022
Blaze Vector Production
Turnkey, scalable, premier research-grade AAV production
- Our proprietary Ignition Cells™ that have a clear, well-documented history and are optimized for scalable suspension growth
- Established process for many standard AAV serotypes
- Upfront communication and pricing
- Fast turnaround time
Process & Analytical Development
End-to-end capabilities from research to cGMP, reducing the need for bridging studies.
- Experienced team able to support process development and scale up
- In-house analytical assay development and performance to support cGMP-readiness
- Process development to manufacture novel engineered capsids
Fully disposable, closed system processing.
- Flexible scheduling and maximization of capacity
- Consistent process and product flow for reduction of variation
- 50-5,000L scale. See our 5,000L bioreactor!
Our Advanced Technologies
At Forge, our platform approach employs the triple plasmid transfection method – the industry standard method for manufacturing AAV. This method is bolstered by Forge’s proprietary technologies, our Ignition Cells™ and pEMBR™ adenovirus helper plasmid.
- Royalty-free license for clients
- Clonal HEK293 mammalian suspension cell line
- Optimized for robust transient transfection
- Animal component free
- Scalable production